Concepedia

Publication | Open Access

Rab25 promotes erlotinib resistance by activating the β1 integrin/AKT/β‐catenin pathway in NSCLC

DOIFull Paper Access

38

Citations

21

References

2019

Year

Jianmin Wang, Pu Zhou, Xudong Wang, Yongxin Yu, Guangkuo Zhu, Linpeng Zheng, Zihan Xu, Feng Li, Qiai You, Qiao Yang,
Cell Proliferation

Abstract

Rab25 mediates erlotinib resistance by activating the β1 integrin/AKT/β-catenin signalling pathway. Rab25 may be a predictive biomarker and has potential therapeutic value in NSCLC patients with acquired resistance to EGFR-TKI.

References

YearCitations

Page 1